What is Cipla Ltd's PE ratio?

Cipla Ltd trades at a P/E ratio of 31.30.

What is Cipla Ltd's market cap?

Cipla Ltd's market capitalisation is ₹1.12L Cr.

When did Cipla Ltd last report results?

Cipla Ltd last reported Q1FY27 results on 23 Jul '26.

What is Cipla Ltd's ROE?

Cipla Ltd's return on equity (ROE) is 11.6%.

What sector is Cipla Ltd in?

Cipla Ltd (CIPLA) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Cipla Ltd (CIPLA)

₹1,395.00

Mkt cap

₹1.12L Cr

P/E ratio

31.30

P/B

3.27

Div yield

0.94%

ROE

11.60%

ROCE

15.50%

EPS (TTM)

₹44.57

Book value

₹426

52W range

1,192–1,664

Sector

Healthcare

Price history

Previous close

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]

NSE CIPLABSE 500087

Health check

Mixed

ValuationFair

ProfitabilityAverage

GrowthModerate

TechnicalsNeutral

52-week range

−16.15% from high

₹1,395

₹1,192+16.99% from low₹1,664

Current

₹1,395.00

Prev close

₹1,385.00

Day

+0.72%

Price performance

+0.72%

−1.01%

−4.70%

+1.34%

+6.23%

−12.11%

YTD

−7.71%

Financials

Revenue, profit & margin

P/E ratio

31.3×

CIPLA is 8% below the sector median of 34.0×

CIPLA31.3×

Sector median34.0×

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	6,329	6,678	6,604	6,163	6,694	7,051	7,073	6,730	6,957	7,589	7,074	6,541	7,119
Expenses	4,835	4,944	4,856	4,847	4,978	5,165	5,084	5,192	5,179	5,695	5,819	5,586	5,927
Operating Profit	1,494	1,734	1,748	1,316	1,716	1,886	1,989	1,538	1,778	1,895	1,255	955	1,192
OPM %	24%	26%	26%	21%	26%	27%	28%	23%	26%	25%	18%	15%	17%
Other Income	136	176	-10	249	160	191	222	289	259	269	-70	148	211
Interest	16	26	30	18	18	15	15	14	14	13	14	13	17
Depreciation	239	290	233	288	247	272	280	309	253	297	278	383	304
Profit before tax	1,375	1,594	1,474	1,259	1,611	1,789	1,916	1,504	1,770	1,854	893	707	1,082
Tax %	28%	28%	28%	26%	27%	27%	17%	19%	27%	27%	24%	22%	27%
Net Profit	998	1,155	1,068	932	1,175	1,305	1,575	1,214	1,292	1,353	674	543	786
EPS in Rs	12.33	14.01	13.08	11.63	14.58	16.13	19.45	15.13	16.06	16.73	8.37	6.87	9.77
Raw PDF

Earnings

Results dates & reactions

No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −0.17% · closed higher next day 22 of last 62

	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Broadcast	28 Oct '23◦	22 Jan '24◦	11 May '24◦	26 Jul '24◦	29 Oct '24◦	29 Jan '25	13 May '25◦	25 Jul '25	30 Oct '25	23 Jan '26	13 May '26	23 Jul '26
Earnings day	+1.64%	+7.05%	+5.61%	−1.34%	−4.01%	+0.24%	−1.66%	+3.00%	−2.59%	−4.04%	+2.73%	−1.56%
+1 day	+2.19%	+7.68%	+1.33%	−2.93%	+5.02%	+2.59%	−1.18%	+5.65%	−5.05%	−4.19%	+11.17%	−0.32%
+5 days	+2.54%	+2.64%	+4.82%	−3.81%	+6.67%	+2.00%	−2.48%	+1.00%	−4.77%	−4.29%	+8.30%	+3.63%
+15 days	+6.73%	+8.29%	+8.42%	−0.77%	+1.74%	+4.33%	−3.17%	+5.20%	−4.38%	−1.02%	+8.23%	+3.09%
+30 days	+3.60%	+12.84%	+11.96%	+3.62%	−1.97%	+2.37%	−0.66%	+4.28%	−4.03%	−2.69%	+11.44%	−1.44%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	PDF	XBRL	PDF	XBRL

Corporate actions

Last 6 months

Kind	Value	Ex-date	Record
dividend Dividend - Rs 13 Per Share	13.00	5 Jun '26	5 Jun '26

Results analysis

Shareholding

as of Jun 2026

29.22%Promoter

Promoters29.22%

FIIs20.20%2.35

DIIs34.35%2.64

Public15.93%0.33

Government0.28%0.01

Ownership trend

Peers

7 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
SUNPHARMA	₹1,899.00	36.07	4,55,634	0.84%	2,901	+5.95%	15,300	+10.46%	20.53%
DIVISLAB	₹9,100.00	81.09	2,41,576	0.33%	902	+65.50%	3,080	+27.80%	21.97%
TORNTPHARM	₹4,857.00	82.80	1,84,745	0.78%	566	+5.79%	4,921	+54.85%	15.19%
CIPLA	₹1,385.00	31.26	1,11,888	0.94%	786	−39.19%	7,119	+2.33%	15.49%
ZYDUSLIFE	₹1,120.00	22.95	1,11,720	0.09%	990	−35.09%	8,017	+21.96%	21.14%
LAURUSLABS	₹1,840.00	90.93	99,417	0.11%	362	+125.49%	2,026	+29.10%	17.76%
LUPIN	₹2,110.00	16.20	96,483	0.85%	1,417	+16.08%	8,277	+32.04%	29.93%
Median: 158 Co.	₹421.50	33.96	2,277	0.08%	13	+30.25%	164	+18.67%	14.96%

Filings

Annual reports15

Annual Report 2026bse Annual Report 2025bse Annual Report 2024bse Annual Report 2023bse Annual Report 2022bse Annual Report 2021bse Annual Report 2020bse Annual Report 2019bse Annual Report 2018bse Annual Report 2017bse Annual Report 2016bse Annual Report 2015bse Annual Report 2014bse Annual Report 2013bse Annual Report 2012bse

Credit ratings6

Rating update 19 Dec 2025fitch Rating update 26 Aug 2025care Rating update 20 Dec 2024fitch Rating update 8 Oct 2024care Rating update 11 Jan 2024fitch Rating update 9 Oct 2023care

Announcements5

Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Sep - Cipla and Qilu ink exclusive US licensing and supply deal for pembrolizumab biosimilar QL2107.Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company 3 Sep - NCLT-directed notice on Inzpera Healthsciences merger with Cipla; objections invited within 30 days.Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep - Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares Announcement under Regulation 30 (LODR)-Press Release / Media Release 31 Aug - Cipla signs exclusive license with SBP Group for HER2 ADC TQB2102 in India, South Africa and five markets.Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA 28 Aug - USFDA classified InvaGen's Central Islip inspection as VAI on 28 August 2026.